Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis

Published:2022-02 Issue: Volume:58 Page:103446
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Zhou Ran,Li Hongliang,Yang Huan,Jiang Fei,Cai Haobing,Li Jing,Chen Si,Fang Liangjuan,Yin Jun,Zeng Qiuming

Funder

National Natural Science Foundation of China

Natural Science Foundation of Hunan Province

Health and Family Planning Commission of Hunan Province

Hunan University of Chinese Medicine

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference53 articles.

1. Teriflunomide and its mechanism of action in multiple sclerosis;Bar-Or;Drugs,2014

2. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis;Barro;Brain,2018

3. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis;Bjornevik;JAMA Neurol.,2020

4. T cell cytokine signatures: biomarkers in pediatric multiple sclerosis;Cala;J. Neuroimmunol.,2016

5. Cantó, E., Barro, C., Zhao, C., Caillier, S.J., Michalak, Z., Bove, R., Tomic, D., Santaniello, A., Häring, D.A., Hollenbach, J., Henry, R.G., Cree, B.A.C., Kappos, L., Leppert, D., Hauser, S.L., Benkert, P., Oksenberg, J.R., Kuhle, J., 2019. Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 Years 1–8. 10.1001/jamaneurol.2019.2137.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Study of Serum Neurofilament Light Chain Levels in Ocrelizumab-Treated People with Relapsing Multiple Sclerosis;Journal of Personalized Medicine;2024-06-27

2. Sustained Effectiveness and Safety Over Time of Teriflunomide in Chinese Patients with Relapsing Multiple Sclerosis in the Greater Bay Area of China: Insights from Real-World Data;Neurology and Therapy;2024-05-16

3. Real-world experience of teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions may play a role;Frontiers in Immunology;2024-03-13

4. The effectiveness of teriflunomide in patients with multiple sclerosis in China: a real-world comparison to no DMT treatment in the first year after diagnosis;Therapeutic Advances in Neurological Disorders;2023-01

5. Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis;PLOS ONE;2022-09-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3